Reply to Aitken et al., "Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?"

Antimicrob Agents Chemother. 2017 Aug 24;61(9):e01163-17. doi: 10.1128/AAC.01163-17. Print 2017 Sep.

Authors

Lucy Cheng¹, Brian C Nelson², Monica Mehta², Qiuhu Shi³, Angela Gomez-Simmonds¹, Anne-Catrin Uhlemann⁴

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
² NewYork-Presbyterian Hospital, New York, New York, USA.
³ New York Medical College, Valhalla, New York, USA.
⁴ Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA au2110@columbia.edu.

No abstract available

Publication types

Comment

MeSH terms

Anti-Bacterial Agents
Bacterial Proteins
Enterobacteriaceae*
Microbial Sensitivity Tests
Penicillanic Acid / analogs & derivatives
Piperacillin*
Tazobactam
beta-Lactamase Inhibitors
beta-Lactamases

Substances

Anti-Bacterial Agents
Bacterial Proteins
beta-Lactamase Inhibitors
Penicillanic Acid
AmpC beta-lactamases
beta-Lactamases
Tazobactam
Piperacillin